Comparative Pharmacology
Head-to-head clinical analysis: ALTOPREV versus FLOLIPID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTOPREV versus FLOLIPID.
ALTOPREV vs FLOLIPID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
Flolipid (simvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
None Documented
None Documented
14 hours (terminal); extended-release formulation allows once-daily dosing
Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing.
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)